1. Home
  2. RBCAA vs SNDX Comparison

RBCAA vs SNDX Comparison

Compare RBCAA & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Republic Bancorp Inc.

RBCAA

Republic Bancorp Inc.

HOLD

Current Price

$96.46

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

N/A

Current Price

$19.84

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RBCAA
SNDX
Founded
1974
2005
Country
United States
United States
Employees
N/A
298
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
RBCAA
SNDX
Price
$96.46
$19.84
Analyst Decision
Hold
Strong Buy
Analyst Count
1
13
Target Price
N/A
$38.69
AVG Volume (30 Days)
97.7K
1.3M
Earning Date
04-23-2026
04-30-2026
Dividend Yield
2.41%
N/A
EPS Growth
N/A
11.56
EPS
0.77
N/A
Revenue
$417,495,000.00
$172,352,000.00
Revenue This Year
$3.93
$107.19
Revenue Next Year
N/A
$41.88
P/E Ratio
$125.66
N/A
Revenue Growth
8.50
627.84
52 Week Low
$63.97
$13.00
52 Week High
$102.22
$25.59

Technical Indicators

Market Signals
Indicator
RBCAA
SNDX
Relative Strength Index (RSI) 52.55 45.62
Support Level $88.24 $19.28
Resistance Level $102.11 $22.40
Average True Range (ATR) 2.26 0.98
MACD -0.68 0.00
Stochastic Oscillator 23.11 74.89

Price Performance

Historical Comparison
RBCAA
SNDX

About RBCAA Republic Bancorp Inc.

Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: